• Amy Wiser, Jeffrey D Quinlan, and Pelin Batur.
• Assistant Professor, Department of Family Medicine, Oregon Health & Science University, Portland, OR; US Cervical Cancer Screening Risk-Based Management Guidelines Research Steering, Colposcopy, and Communication Committees wisera@ohsu.edu.
• Cleve Clin J Med. 2021 Oct 1; 88 (10): 556-560.

AbstractIn making the 2019 guidelines for risk-based management of patients with abnormal cervical cancer screening tests and cancer precursors, the guidelines committee shifted from results-based to risk-based management recommendations, based on the patient's immediate and 5-year risks of grade 3 or higher cervical intraepithelial neoplasia (CIN 3+). The risk is determined by current and prior screening results (human papillomavirus infection, cytology testing) and the clinical history including age. An immediate 4% or higher risk of CIN 3+ was established as the dividing line between higher and lower risks, and the corresponding management recommendations. This article reviews the changes and their evidence base and discusses clinical implications of the revised guidelines.Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

13 keywords...

hide…